Gilead to Withdraw US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer

OncLive·Oct 18

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Gilead is withdrawing the US indication for sacituzumab govitecan in metastatic urothelial cancer, also known as bladder cancer. The withdrawal appears to be related to a negative trial, which reportedly showed a lack of survival benefit. The drug, also known as Trodelvy, may still be approved for other uses, such as metastatic triple-negative breast cancer.

Full coverage

Bladder Cancer Indication of Sacituzumab Govitecan Withdrawn in US

Targeted Oncology·Oct 21

Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status

CancerNetwork·Oct 29

Sacituzumab govitecan withdrawn from bladder cancer market following negative trial

Urology Times·Oct 21

Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial

The ASCO Post·Oct 21

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Gilead Sciences·Jun 24

Sacituzumab Govitecan (Trodelvy) Withdrawn in Bladder Cancer Due to Lack of Survival Benefit

Oncology News Central·Oct 21

FDA Approval of Trodelvy Withdrawn for Urothelial Carcinoma

Cure Today·Oct 22

in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

Business Wire·May 21

View original report at OncLive ↗

Fetching the latest headlines…